Taken together, these findings indicate that the expression of PTGS2, NFE2L2, and HMOX1 correlates with poor clinical outcomes and may be exploited as diagnostic and/or therapeutic targets in breast cancer. Here, NFE2L2 is linked to breast carcinoma.